Extendicare Inc. (TSE:EXE – Get Free Report)’s stock price reached a new 52-week high on Monday . The company traded as high as C$13.13 and last traded at C$13.08, with a volume of 67465 shares. The stock had previously closed at C$13.04.
Analysts Set New Price Targets
EXE has been the subject of a number of recent research reports. Cormark raised Extendicare to a “moderate buy” rating in a research report on Wednesday, February 19th. TD Securities upped their price objective on Extendicare from C$10.50 to C$13.00 and gave the stock a “hold” rating in a research note on Monday, March 3rd. BMO Capital Markets upped their price objective on Extendicare from C$11.00 to C$13.50 in a research note on Monday, March 3rd. Finally, Royal Bank of Canada upped their price objective on Extendicare from C$9.50 to C$11.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 28th.
Extendicare Trading Up 0.1 %
Extendicare Announces Dividend
The firm also recently declared a monthly dividend, which will be paid on Monday, March 17th. Investors of record on Monday, March 17th will be paid a $0.04 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 3.67%. The ex-dividend date of this dividend is Friday, February 28th. Extendicare’s dividend payout ratio (DPR) is presently 61.20%.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Featured Articles
- Five stocks we like better than Extendicare
- Consumer Staples Stocks, Explained
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Airline Stocks – Top Airline Stocks to Buy Now
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- Insider Selling Explained: Can it Inform Your Investing Choices?
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.